Entry into the pharmaceutical CDMO business and a ¥20 billion sales target for 2030
First written in FY2024. 2 of 3 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「Through this acquisition, the Company will enter the pharmaceutical CDMO business. By combining 滋賀県製薬’s ability to handle diverse dosage forms and extensive track record with the Group’s management resources, formulation design and quality control capabilities, and advanced production technologies such as automation and digital transformation (DX), the Company aims to strengthen 滋賀県製薬’s manufacturing capabilities.」
The acquisition of 滋賀県製薬 enabled entry into the pharmaceutical CDMO business and gave concrete form to the policy of combining capabilities across dosage forms, customer base, formulation design, quality control, automation and DX toward the target of ¥20 billion in pharmaceuticals sales out of the ¥150 billion 2030 medical sales target. - FY2025-H1AdvancedAnnual report
「For the medical market in particular, the Company has set a sales target of ¥150 billion for 2030, including a ¥20 billion sales target for the pharmaceuticals business. Through this acquisition, the Company will enter the pharmaceutical CDMO business.」
The acquisition of 滋賀県製薬 was completed on 8 January 2025, enabling the Company to enter the pharmaceutical CDMO business. Toward the target of ¥20 billion in pharmaceuticals sales out of the ¥150 billion 2030 medical sales target, the Company aims to expand the business by combining its capabilities across dosage forms, customer base, formulation design, quality control, automation and DX. - FY2024First statedAnnual report
「For the medical market in particular, the Company has set a sales target of ¥150 billion for 2030, including a ¥20 billion sales target for the pharmaceuticals business. Through this acquisition, the Company will enter the pharmaceutical CDMO business.」
Through the acquisition of 滋賀県製薬 on 8 January 2025, the Company announced its entry into the pharmaceutical CDMO business and a new target breakdown of ¥20 billion in pharmaceuticals sales out of the ¥150 billion 2030 medical sales target. The Company aims to expand the business by combining 滋賀県製薬’s diverse dosage forms and customer base with the Group’s formulation design, quality control, automation and DX capabilities.